References
- Zimran A, Elstein D. Lipid storage diseases. In: Williams Hematology (8th Edition). Lichtman MA, Kipps T, Seligsohn U, Kaushansky K, Prchal JT (Eds). McGraw-Hill, New York, NY, USA, 1065–1071 (2010).
- Barton NW, Brady RO, Dambrosia JM et al. Replacement therapy for inherited enzyme deficiency – macrophage-targeted glucocerebrosidase for Gaucher’s disease. N. Engl. J. Med. 324(21), 1464–1470 (1991).
- Grabowski GA, Barton NW, Pastores G et al. Enzyme therapy in type 1 Gaucher disease: comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources. Ann. Intern. Med. 122(1), 33–39 (1995).
- Zimran A, Elstein D, Levy-Lahad E et al. Replacement therapy with imiglucerase for type 1 Gaucher’s disease. Lancet 345(8963), 1479–1480 (1995).
- Zimran A, Loveday K, Fratazzi C, Elstein D. A pharmacokinetic analysis of a novel enzyme replacement therapy with Gene-Activated human glucocerebrosidase (GA-GCB) in patients with type 1 Gaucher disease. Blood Cells Mol. Dis. 39(1), 115–118 (2007).
- Brumshtein B, Salinas P, Peterson B et al. Characterization of gene-activated human acid-beta-glucosidase: crystal structure, glycan composition, and internalization into macrophages. Glycobiology 20(1), 24–32 (2010).
- Zimran A, Altarescu G, Philips M et al. Phase 1/2 and extension study of velaglucerase alfa replacement therapy in adults with type 1 Gaucher disease: 48-month experience. Blood 115(23), 4651–4656 (2010).
- Pastores GM, Weinreb NJ, Aerts H et al. Therapeutic goals in the treatment of Gaucher disease. Semin. Hematol. 41(4 Suppl. 5), 4–14 (2004).
- Czartoryska B, Tylki-Szymanska A, Górska D. Serum chitotriosidase activity in Gaucher patients on enzyme replacement therapy (ERT). Clin. Biochem. 31(5), 417–420 (1998).
- Boot RG, Verhoek M, de Fost M et al. Marked elevation of the chemokine CCL18/PARC in Gaucher disease: a novel surrogate marker for assessing therapeutic intervention. Blood 103(1), 33–39 (2004).
- Elstein D, Cohn GM, Wang N, Djordjevic M, Brutaru C, Zimran A. Early achievement and maintenance of the therapeutic goals using velaglucerase alfa in type 1 Gaucher disease. Blood Cells Mol. Dis. 46(1), 119–123 (2011).
- Khan A, Hangartner T, Weinreb NJ, Taylor JS, Mistry PK. Risk factors for fractures and avascular osteonecrosis in type 1 Gaucher disease: a study from the International Collaborative Gaucher Group (ICGG) Gaucher Registry. J. Bone Miner. Res. 27(8), 1839–1848 (2012).
- Elstein D, Foldes AJ, Zahrieh D et al. Significant and continuous improvement in bone mineral density among type 1 Gaucher disease patients treated with velaglucerase alfa: 69-month experience, including dose reduction. Blood Cells Mol. Dis. 47(1), 56–61 (2011).
- Maas M, van Kuijk C, Stoker J et al. Quantification of bone involvement in Gaucher disease: MR imaging bone marrow burden score as an alternative to Dixon quantitative chemical shift MR imaging–initial experience. Radiology 229(2), 554–561 (2003).
- Robertson PL, Maas M, Goldblatt J. Semiquantitative assessment of skeletal response to enzyme replacement therapy for Gaucher’s disease using the bone marrow burden score. AJR. Am. J. Roentgenol. 188(6), 1521–1528 (2007).
- Elstein D, Haims AH, Zahrieh D, Cohn GM, Zimran A. Impact of Velaglucerase Alfa Therapy on Bone Marrow Burden Score in Adults with Type 1 Gaucher Disease: 7-Year Experience. European Working Group for Gaucher Disease (EWGGD). Paris, France, 27–30 June 2012.
- Gonzalez DE, Turkia HB, Lukina EA et al. Enzyme replacement therapy with velaglucerase alfa in Gaucher disease: results from a randomized, double-blind, multinational, Phase 3 study. Am. J. Hematol. 88(3), 166–171 (2013).
- Zimran A, Pastores GM, Tylki-Szymanska A et al. Safety and efficacy of velaglucerase alfa in Gaucher disease type 1 patients previously treated with imiglucerase. Am. J. Hematol. 88(3), 172–178 (2013).
- Ben Turkia H, Gonzalez DE, Barton NW et al. Velaglucerase alfa enzyme replacement therapy compared with imiglucerase in patients with Gaucher disease. Am. J. Hematol. 88(3), 179–184 (2013).
- Grabowski GA, Kacena K, Cole JA et al. Dose-response relationships for enzyme replacement therapy with imiglucerase/alglucerase in patients with Gaucher disease type 1. Genet. Med. 11(2), 92–100 (2009).
- Hollak CE, vom Dahl S, Aerts JM et al. Force majeure: therapeutic measures in response to restricted supply of imiglucerase (Cerezyme) for patients with Gaucher disease. Blood Cells Mol. Dis. 44(1), 41–47 (2010).
- Hughes DA, Al-Sayed M, Belmatoug N et al. Early access experience with VPRIV®: recommendations for ‘core data’ collection. Blood Cells Mol. Dis. 47(2), 140–142 (2011).
- Elstein D, Altarescu G, Maayan H et al. Booster-effect with velaglucerase alfa in patients with Gaucher disease switched from long-term imiglucerase therapy: early Access Program results from Jerusalem. Blood Cells Mol. Dis. 48(1), 45–50 (2012).
- Zimran A, Brill-Almon E, Chertkoff R et al. Pivotal trial with plant cell-expressed recombinant glucocerebrosidase, taliglucerase alfa, a novel enzyme replacement therapy for Gaucher disease. Blood 118(22), 5767–5773 (2011).
- Ilan Y, Elstein D, Zimran A. Glucocerebroside: an evolutionary advantage for patients with Gaucher disease and a new immunomodulatory agent. Immunol. Cell Biol. 87(7), 514–524 (2009).
- Lukina E, Watman N, Arreguin EA et al. Improvement in hematological, visceral, and skeletal manifestations of Gaucher disease type 1 with oral eliglustat tartrate (Genz-112638) treatment: 2-year results of a Phase 2 study. Blood 116(20), 4095–4098 (2010).
Websites
- ClinicalTrials.gov identifier: NCT00391625. http://www.clinicaltrials.gov/ct2/show/NCT00391625
- ClinicalTrials.gov identifier: NCT00430625. http://www.clinicaltrials.gov/ct2/show/NCT00430625
- ClinicalTrials.gov identifier: NCT00478647 http://www.clinicaltrials.gov/ct2/show/NCT00478647
- ClinicalTrials.gov identifier: NCT00553631. http://www.clinicaltrials.gov/ct2/show/NCT00553631